Biotech firm Ovid develops Takeda drug | Chemical & Engineering News
Volume 95 Issue 4 | p. 12 | Concentrates
Issue Date: January 23, 2017

Biotech firm Ovid develops Takeda drug

Department: Business
Keywords: rare disease, epilepsy, Takeda

In a reverse of the usual big pharma-biotech relationship, the New York City-based biotech firm Ovid Therapeutics will help develop a Takeda Pharmaceutical drug for rare pediatric epilepsy. The drug, a small molecule called TAK-935, inhibits the enzyme cholesterol 24-hydroxylase, which may have a role in central nervous system diseases such as epilepsy. In the deal, Takeda received equity in Ovid, which specializes in rare neurological diseases. The two firms will share any profits on a 50-50 basis.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment